DDInter557 DDInter233
A 9,10alpha-dihydro derivative of [ergotamine]. Dihydroergotamine is used as an abortive therapy for migraines. Its use has largely been supplanted by triptans in current therapy due to the class's greater selectivity and more favourable side effect profile. Recent improvements have been made in the design of intranasal delivery devices allowing for greater delivery of dihydroergotamine solution to the vasculature-rich upper nasal cavity. The recently approved Precision Olfactory Delivery technology developed by Impel Neuropharma technology has correlated with an increase of 3-fold in Cmax and 4-fold in AUC despite the solution formulated at 75% of the strength of the existing intranasal product.
Brigatinib, originally named AP26113, is a reversible dual inhibitor of anaplastic lymphoma kinase (ALK) and epidermal growth factor receptor (EGFR). It presents selectivity against the mutant forms of EGFR compared to the wild-type. It also exhibits selectivity against 9 different Crizotinib-resistant mutants of the EML4-ALK fusion gene, which is a pivotal player in the transformation of susceptible lung parenchyma. Brigatinib was developed by Ariad Pharmaceuticals, a subsidiary of Takeda Pharmaceutical Company Limited, and FDA-approved on April 28, 2017.
Dihydroergotamine {u} (Compound) resembles {v} (Compound) Ergotamine
Ergotamine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Brigatinib
Dihydroergotamine {u} (Compound) resembles {v} (Compound) Ergotamine
Ergotamine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Sirolimus
Sirolimus {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Brigatinib
Dihydroergotamine {u} (Compound) resembles {v} (Compound) Ergoloid mesylate
Ergoloid mesylate {u} (Compound) resembles {v} (Compound) Bromocriptine
Bromocriptine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Brigatinib
Dihydroergotamine {u} (Compound) resembles {v} (Compound) Bromocriptine
Bromocriptine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Sirolimus
Sirolimus {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Brigatinib
Dihydroergotamine {u} (Compound) binds {v} (Gene) ABCB1
ABCB1 {u} (Gene) is bound by {v} (Compound) Amprenavir
Amprenavir {u} may lead to a major life threatening interaction when taken with {v} Brigatinib
Dihydroergotamine {u} (Compound) resembles {v} (Compound) Bromocriptine
Bromocriptine {u} (Compound) resembles {v} (Compound) Ergometrine
Ergometrine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Brigatinib
Dihydroergotamine {u} (Compound) binds {v} (Gene) ADRA2A
ADRA2A {u} (Gene) is bound by {v} (Compound) Amitriptyline
Amitriptyline {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Brigatinib
Dihydroergotamine {u} (Compound) binds {v} (Gene) CYP3A4
CYP3A4 {u} (Gene) is bound by {v} (Compound) Gemfibrozil
Gemfibrozil {u} may cause a minor interaction that can limit clinical effects when taken with {v} Brigatinib
Dihydroergotamine {u} (Compound) resembles {v} (Compound) Bromocriptine
Bromocriptine {u} may cause a minor interaction that can limit clinical effects when taken with {v} Tamoxifen
Tamoxifen {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Brigatinib
Dihydroergotamine {u} (Compound) resembles {v} (Compound) Ergotamine
Ergotamine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Ivosidenib
Ivosidenib {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Brigatinib
Dihydroergotamine (Compound) resembles Ergotamine (Compound) and Ergotamine may cause a moderate interaction that could exacerbate diseases when taken with Brigatinib
Dihydroergotamine (Compound) resembles Ergotamine (Compound) and Ergotamine may cause a moderate interaction that could exacerbate diseases when taken with Sirolimus and Sirolimus may cause a moderate interaction that could exacerbate diseases when taken with Brigatinib
Dihydroergotamine (Compound) resembles Ergoloid mesylate (Compound) and Ergoloid mesylate (Compound) resembles Bromocriptine (Compound) and Bromocriptine may cause a moderate interaction that could exacerbate diseases when taken with Brigatinib
Dihydroergotamine (Compound) resembles Bromocriptine (Compound) and Bromocriptine may cause a moderate interaction that could exacerbate diseases when taken with Sirolimus and Sirolimus may cause a moderate interaction that could exacerbate diseases when taken with Brigatinib
Dihydroergotamine (Compound) binds ABCB1 (Gene) and ABCB1 (Gene) is bound by Amprenavir (Compound) and Amprenavir may lead to a major life threatening interaction when taken with Brigatinib
Dihydroergotamine (Compound) resembles Bromocriptine (Compound) and Bromocriptine (Compound) resembles Ergometrine (Compound) and Ergometrine may cause a moderate interaction that could exacerbate diseases when taken with Brigatinib
Dihydroergotamine (Compound) binds ADRA2A (Gene) and ADRA2A (Gene) is bound by Amitriptyline (Compound) and Amitriptyline may cause a moderate interaction that could exacerbate diseases when taken with Brigatinib
Dihydroergotamine (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Gemfibrozil (Compound) and Gemfibrozil may cause a minor interaction that can limit clinical effects when taken with Brigatinib
Dihydroergotamine (Compound) resembles Bromocriptine (Compound) and Bromocriptine may cause a minor interaction that can limit clinical effects when taken with Tamoxifen and Tamoxifen may cause a moderate interaction that could exacerbate diseases when taken with Brigatinib
Dihydroergotamine (Compound) resembles Ergotamine (Compound) and Ergotamine may cause a moderate interaction that could exacerbate diseases when taken with Ivosidenib and Ivosidenib may cause a moderate interaction that could exacerbate diseases when taken with Brigatinib